What it's for (Indications)
- Nilotinib is indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.
- It is also indicated for the treatment of adult patients with Ph+ CML in chronic phase (CP) and accelerated phase (AP) resistant or intolerant to prior therapy including imatinib.
- The efficacy and safety of nilotinib have been established through robust clinical trials, demonstrating its significant role in achieving hematologic and cytogenetic responses, and improving progression-free and overall survival in eligible patient populations.
- Its use is specifically targeted at patients whose disease expresses the Bcr-Abl fusion protein, characteristic of Ph+ CML.
- Regular monitoring is essential to assess treatment response and manage potential adverse effects throughout the course of therapy.
- This targeted therapy has revolutionized the management of CML, offering a potent option for disease control and improved patient outcomes.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The recommended dosage of nilotinib varies depending on the specific indication. For adult patients with newly diagnosed Ph+ CML in chronic phase, the prescribed dose is 300 mg orally twice daily. For adult patients with Ph+ CML in chronic phase or accelerated phase who are resistant or intolerant to prior therapy, including imatinib, the recommended dose is 400 mg orally twice daily. Nilotinib capsules must be taken strictly on an empty stomach to ensure optimal absorption and minimize variability in drug exposure; this translates to at least 2 hours after any meal and at least 1 hour before the next meal. It is crucial for patients to swallow the capsules whole and not open them. In the event of a missed dose, the patient should not take an extra dose but should continue with the next regularly scheduled dose. Dose adjustments may be necessary based on individual patient tolerance, hematological parameters, or specific adverse events, and must always be made under strict medical supervision. Adherence to the prescribed regimen and timing relative to meals is paramount for maximizing treatment efficacy and ensuring patient safety. |
Safety & Warnings
Common Side Effects
- Nilotinib is associated with a wide range of side effects, some of which are common and others potentially serious, necessitating careful monitoring.
- Common adverse reactions include myelosuppression (e.
- g.
- , thrombocytopenia, neutropenia, anemia), dermatological manifestations such as rash and pruritus, gastrointestinal disturbances including nausea, constipation, diarrhea, and abdominal pain, as well as fatigue, headache, muscle pain, and arthralgia.
- Laboratory abnormalities frequently observed include elevations in lipase, bilirubin, and liver enzymes (ALT, AST).
- More serious adverse events that demand immediate attention and management include significant QT interval prolongation and the associated risk of sudden death, serious cardiovascular events (e.
- g.
- , peripheral arterial occlusive disease, ischemic heart disease, cerebrovascular events), fluid retention (e.
- g.
- , pleural effusion, pericardial effusion, peripheral edema), pancreatic toxicities (e.
- g.
- , pancreatitis), hepatotoxicity, hemorrhage, and tumor lysis syndrome.
- Patients should be thoroughly counseled on these potential side effects and advised to report any new or worsening symptoms promptly to their healthcare provider.
- Regular and comprehensive laboratory monitoring is essential to detect and manage these adverse reactions early in their course.
Serious Warnings
- Black Box Warning: **QT PROLONGATION and SUDDEN DEATH:** Tasigna (nilotinib) can cause prolongation of the QT interval, which may lead to serious and potentially fatal cardiac arrhythmias, including Torsades de Pointes, and sudden death. Do not administer Tasigna to patients with hypokalemia, hypomagnesemia, or long QT syndrome. It is imperative that hypokalemia or hypomagnesemia be corrected to within the normal range prior to initiating Tasigna therapy. Concomitant use of Tasigna with drugs known to prolong the QT interval (e.g., Class IA and III antiarrhythmics, cisapride, pimozide, thioridazine) and strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, grapefruit juice, certain protease inhibitors) must be avoided, as these agents can significantly increase nilotinib exposure and further exacerbate the risk of QT prolongation. **ARTERIAL OCCLUSIVE EVENTS:** Cases of serious arterial occlusive events, some of which were fatal, have been reported in patients receiving Tasigna. These events include peripheral arterial occlusive disease, ischemic heart disease, and cerebrovascular events. Patients should be diligently monitored for signs and symptoms of arterial occlusion throughout treatment, and any existing risk factors for cardiovascular disease should be comprehensively assessed and managed appropriately. These events can occur at any time during treatment and may necessitate treatment interruption or permanent discontinuation of Tasigna.
- Nilotinib carries several critical warnings that necessitate careful patient selection, meticulous monitoring, and proactive management strategies.
- **Cardiovascular Events:** Serious and sometimes fatal arterial occlusive events, including peripheral arterial occlusive disease, ischemic heart heart disease, and cerebrovascular events, have been reported.
- Patients with pre-existing cardiovascular risk factors should be monitored closely, and these risk factors (e.
- g.
- , hypertension, dyslipidemia, diabetes) should be aggressively managed before and throughout nilotinib therapy.
- **QT Prolongation and Sudden Death:** Nilotinib can significantly prolong the QT interval, which markedly increases the risk of potentially fatal Torsades de Pointes.
- Patients with a history of long QT syndrome, or uncorrected hypokalemia or hypomagnesemia, should not receive nilotinib.
- Electrolytes must be corrected to within the normal range prior to initiating therapy and monitored periodically.
- Concomitant use with strong CYP3A4 inhibitors or other medications known to prolong the QT interval should be rigorously avoided.
- **Myelosuppression:** Severe thrombocytopenia, neutropenia, and anemia are common; complete blood counts should be performed every two weeks for the initial 2 months and then monthly thereafter.
- **Hepatotoxicity and Pancreatic Toxicity:** Elevations in liver enzymes and lipase are common, and pancreatitis can occur.
- Liver function tests and lipase levels should be monitored regularly.
- **Fluid Retention:** Edema, pleural effusion, and pericardial effusion have been reported.
- **Tumor Lysis Syndrome:** May occur, especially in patients with high tumor burden; adequate hydration and prophylactic measures are recommended.
- **Drug Interactions:** Avoid co-administration with strong CYP3A4 inhibitors and inducers, and agents that significantly reduce gastric acid.
How it Works (Mechanism of Action)
Nilotinib is a potent and selective oral tyrosine kinase inhibitor (TKI) that specifically targets the Bcr-Abl fusion protein, which is the oncogenic driver in Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML). Its mechanism of action involves binding to the ATP-binding site within the Bcr-Abl kinase domain, stabilizing an inactive conformation of the enzyme. This competitive inhibition of ATP binding prevents the phosphorylation of tyrosine residues on critical downstream signaling proteins, thereby disrupting the aberrant signaling pathways that drive the proliferation and survival of CML cells. By blocking these key pathways, nilotinib effectively induces apoptosis in CML cell lines and primary leukemic cells. Nilotinib demonstrates superior potency against Bcr-Abl compared to imatinib and is active against most imatinib-resistant Bcr-Abl mutations, with the notable exception of the T315I mutation. Additionally, nilotinib exhibits inhibitory activity against other kinases, including c-KIT, platelet-derived growth factor receptor (PDGFR)-alpha, and PDGFR-beta, although its primary clinical efficacy in CML is attributed to its potent and selective Bcr-Abl inhibition. This highly targeted action underpins its significant therapeutic effectiveness in the management of CML.
Commercial Brands (Alternatives)
No other brands found for this formula.